Results from a phase I study of stereotactic body radiation therapy (SBRT) and systemic IL-2 in melanoma and renal cell carcinoma demonstrated that this combination could result in impressive responses in both tumor types (Seung et al., 2012). This evidence concerns the gene IL2 and neoplasm.